期刊
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
卷 8, 期 3, 页码 143-159出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X15576462
关键词
Crohn's Disease; Inflammatory Bowel Disease; biologics; anti-TNF
资金
- Abbvie
- UCB
- Janssen
- Takeda
- Salix
- Prometheus
- Amgen
- Bristol-Meyers Squibb
Crohn's disease (CD) is a debilitating, systemic inflammatory disorder with both gastrointestinal and extraintestinal manifestations. Its existence predates modern medicine, but its precise etiology remains incompletely understood. Most authorities suggest a multifactorial pathogenesis owing to a mixture of genetic disorders, immunologic dysregulation, microbiota disequilibrium and environmental influences. Of these factors, the overactive immunologic response seen in CD appears to be the most promising target of medical therapy. Biological agents comprise a relatively new class of drugs that can induce and maintain remission in moderate to severe CD, as well as in ulcerative colitis. This review will provide an overview of CD, its history, clinical features, pathophysiology, and treatment options focusing on current and future biological agents with an emphasis on drug development, dosage and administration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据